Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Data Sheet 1_Analysis of lymphocytic leukemia trends among gender, race, age, and regional groups in the U.S. between 1999-2022: a CDC-WONDER database study.docx by Shannon Blee (15251230)

“…Statistical significance was set at p ≤0.05.</p>Results<p>Between 1999 and 2022, there was a decrease in overall mortality rates up until 2018, followed by an increase from 2018 to 2022. …”

Image 3_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Image 7_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Image 1_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Image 4_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Image 2_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Image 6_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Image 5_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Image 8_A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.jpeg by Yue Fu (64387)

“…In vivo efficacy was assessed using a xenograft model.</p>Results<p>The MTS and colony formation assays demonstrated that SMCl significantly decreased the viability of HCC cells. …”

Table2_The incidence, mortality and disease burden of cardiovascular diseases in China: a comparative study with the United States and Japan based on the GBD 2019 time trend analys... by Menglan Zhu (10268801)

“…Compared with the US and Japan, from 1990 to 2019, the CVDs incidence rate in China showed an increasing trend, with a lower annual decrease in ASDR and a younger age structure of disease burden. …”

Table1_The incidence, mortality and disease burden of cardiovascular diseases in China: a comparative study with the United States and Japan based on the GBD 2019 time trend analys... by Menglan Zhu (10268801)

“…Compared with the US and Japan, from 1990 to 2019, the CVDs incidence rate in China showed an increasing trend, with a lower annual decrease in ASDR and a younger age structure of disease burden. …”

Table3_The incidence, mortality and disease burden of cardiovascular diseases in China: a comparative study with the United States and Japan based on the GBD 2019 time trend analys... by Menglan Zhu (10268801)

“…Compared with the US and Japan, from 1990 to 2019, the CVDs incidence rate in China showed an increasing trend, with a lower annual decrease in ASDR and a younger age structure of disease burden. …”

Table 1_Adjuvant melatonin therapy during exercise prescription in breast cancer survivors on physical and anthropometric parameters, quality of life, and hormonal response. A rand... by Ana M. Celorrio San Miguel (21583961)

“…</p>Results<p>After 10 weeks, both groups showed a non-significant decrease (p > 0.05) in fat mass. …”

<b>Dataset of a </b><b>phase Ib clinical study: </b><b>rapid regression of high-risk carotid hemorrhagic </b><b>plaques with sonodynamic therapy</b> by Ye Tian (22423790)

“…The primary endpoint demonstrated a significant decrease in maximum wall thickness (MaxWT) at 1 month post-SDT in all plaques, particularly IPH plaques. …”

Table 3_Comparative performance evaluation of large language models in answering esophageal cancer-related questions: a multi-model assessment study.xlsx by Zijie He (8194938)

“…Retesting showed improvements in overall quality, yet some responses showed decreased completeness and relevance.</p>Conclusion<p>Large language models have considerable potential in answering questions about esophageal cancer, with significant differences in completeness. …”